Home | Welcome to Contract Pharma   
Last Updated Wednesday, May 27 2015

Print RSS Feed

Financial Report: Akorn

By Kristin Brooks

Published March 3, 2014
Related Searches: Development

4Q Revenues: $85.0 million (+19%)

4Q Earnings: $16.7 million (+89%)

FY Revenues: $317.7 million (+24%)

FY Earnings: $52.4 million (+48%)

Comments: In the quarter, the company announced the acquisition of Hi-Tech Pharmacal, expanding its branded ophthalmic portfolio, filed 12 ANDAs and completed the development of an additional 11 ANDAs, and completed the acquisition of the U.S. rights to three branded ophthalmic products from Merck: AzaSite, COSOPT and COSOPT PF. The company’s overall gross profit margin was down 6% due to a significant percentage of Akorn’s revenue growth coming from products that were contract manufactured, some of which include profit sharing arrangements with development partners.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On